Previous 10 | Next 10 |
AxoGen, Inc. (AXGN) Q4 2018 Earnings Conference Call February 26, 2019 4:30 PM ET Company Participants Kaila Krum - Vice President, Investor Relations & Corporate Development Karen Zaderej - Chairman, Chief Executive Officer & President Pete Mariani - Chief Financial Offi...
The following slide deck was published by AxoGen, Inc. in conjunction with their 2018 Q4 earnings Read more ...
RADNOR, Pa., Feb. 26, 2019 (GLOBE NEWSWIRE) -- The law firm of Kessler Topaz Meltzer & Check, LLP reminds AxoGen, Inc. (Nasdaq: AXGN) (“AxoGen”) investors that a securities fraud class action lawsuit has been filed in the United States District Court for the Middle D...
AxoGen (NASDAQ: AXGN ): Q4 Non-GAAP EPS of -$0.09 beats by $0.01 ; GAAP EPS of -$0.13 misses by $0.03 . Revenue of $23.4M (+37.6% Y/Y) misses by $0.22M . Press Release More news on: AxoGen, Inc., Earnings news and commentary, Healthcare stocks news,
Fourth Quarter Revenue of $23.4 million, representing 38% growth over prior year Full Year 2018 Revenue of $83.9 million, representing 39% growth over prior year ALACHUA, Fla., Feb. 26, 2019 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing i...
AAXN , ACAD , AKCA , ARNA , AXGN , BGS , BNFT , CERS , CLGX , CPE , CSGP , CW , DRQ , DVAX , ELF , ENPH , EOG , EVH , FOXF , FRPT , FTR , GWPH , HEI , HPR , HURN , HY , ICFI , IMAX , IMMR , INGN , INN , INSP , JAZZ , JBGS , MASI , MED , MELI , MGRC , M...
ALACHUA, Fla., Feb. 19, 2019 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for damage or discontinuity to peripheral nerves, today announced that members of its management team will participate in two investor conf...
ALACHUA, Fla., Feb. 14, 2019 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for damage or discontinuity to peripheral nerves, today announced that it will report fourth quarter and full year 2018 financial resu...
NEW YORK, Feb. 12, 2019 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors, traders, and shareholders of Digital Realty Trust, Inc. (NYSE:DLR), Iridium Communications Inc (NAS...
SAN FRANCISCO, Feb. 04, 2019 (GLOBE NEWSWIRE) -- Hagens Berman Sobol Shapiro LLP reminds investors in Axogen, Inc. (NASDAQ: AXGN) of the March 11, 2019 Lead Plaintiff deadline in the pending securities class action. If you purchased or otherwise acquired AxoGen securities between A...
News, Short Squeeze, Breakout and More Instantly...
ALACHUA and TAMPA, Fla., July 23, 2024 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, today announced that it will report second quarter 2024 financial results on Thursday, August 8, 2024, b...
2024-07-01 07:30:05 ET Raymond James analyst issues OUTPERFORM recommendation for AXGN on July 1, 2024 05:51AM ET. AXGN was trading at $7.24 at issue of the analyst recommendation. Historical Analyst Recommendations Latest 10 recommendations
ALACHUA, Fla. and TAMPA, Fla., July 01, 2024 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, announced making an inducement grant on July 1, 2024, under NASDAQ listing rule 5635(c)(4) in conn...